Beam Therapeutics (NASDAQ: BEAM) details Q2 loss, $1.2B cash and pipeline plans
Rhea-AI Filing Summary
Beam Therapeutics Inc. reported results for the quarter ended June 30, 2026 and highlighted significant clinical milestones across its base-editing portfolio. License and collaboration revenue was $490 thousand. The company reported a net loss of $122.7 million, or $1.18 per share, and ended the quarter with $1.2 billion in cash, cash equivalents and marketable securities.
Beam expects its June 30, 2026 cash balance, together with $200 million expected from a credit facility with Sixth Street, to fund operations into mid-2029. Clinically, the first patient was dosed in the global pivotal cohort of the BEAM-302 AATD trial, dosing was completed in the BEACON risto-cel SCD trial with a planned BLA submission as early as year-end 2026, and the FDA cleared the IND for BEAM-304 in PKU. BEAM-301 continues in a Phase 1/2 GSDIa trial with initial data expected in 2026.
Positive
- None.
Negative
- None.
8-K Event Classification
Key Figures
Key Terms
biologics license application (BLA) regulatory
investigational new drug (IND) application regulatory
accelerated approval regulatory
base editing technical
lipid nanoparticle (LNP) technical
phenylketonuria (PKU) medical
Earnings Snapshot
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What were Beam Therapeutics (BEAM) key financial results for Q2 2026?
How much cash does Beam Therapeutics (BEAM) have and what is its runway?
What progress did Beam Therapeutics (BEAM) report on the BEAM-302 AATD program?
What are the next steps for risto-cel in sickle cell disease at Beam Therapeutics (BEAM)?
What regulatory milestone did Beam Therapeutics (BEAM) achieve for BEAM-304 in PKU?
Which pipeline programs did Beam Therapeutics (BEAM) highlight beyond BEAM-302 and risto-cel?
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
|
|
|||
(State or other jurisdiction |
|
(Commission |
|
(IRS Employer |
of incorporation) |
|
File Number) |
|
Identification No.) |
|
|
|
|
|
|
|
|
|
|
|
|
|
||
(Address of principal executive offices) |
|
|
|
(Zip Code) |
(Registrant’s telephone number, including area code): (
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act: |
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On August 4, 2026, the Company issued a press release announcing its financial results for the quarter ended June 30, 2026. A copy of this press release is furnished as Exhibit 99.1 and is incorporated herein by reference.
The information in this Item 2.02 as well as in the accompanying Exhibit 99.1 attached hereto is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing by the Company, under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No. |
|
Description |
|
|
|
99.1 |
|
Press Release Issued by Beam Therapeutics Inc. on August 4, 2026 |
104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
BEAM THERAPEUTICS INC. |
|
|
|
|
|
Date: August 4, 2026 |
|
By: |
/s/ John Evans |
|
|
Name: |
John Evans |
|
|
Title: |
Chief Executive Officer |
Exhibit 99.1
Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD)
Updated BEAM-302 Phase 1/2 Clinical Data Selected for Late-Breaking Oral Presentation at the European Respiratory Society (ERS) Congress 2026
Dosing Complete for All Adult and Adolescent Patients in Phase 1/2 BEACON Trial of Risto-cel in Sickle Cell Disease; U.S. Biologics License Application (BLA) Submission Expected as Early as Year-End 2026
Clinical Trial Start-up Activities Underway Following U.S. FDA Clearance of Investigational New Drug (IND) Application for BEAM-304 in Phenylketonuria (PKU)
Ended Second Quarter 2026 with $1.2 Billion in Cash, Cash Equivalents and Marketable Securities; Cash Runway Expected to Support Operating Plans into mid-2029
Cambridge, Mass., August 4, 2026 – Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today reported second quarter 2026 financial results and provided updates across the company’s hematology and genetic disease franchises.
“The second quarter marked another period of rapid progress and disciplined execution on the clinical, regulatory and operational milestones we set for Beam,” said John Evans, chief executive officer of Beam Therapeutics. “Importantly, this progress enabled dosing of the first patient in the global pivotal cohort evaluating BEAM-302, the most advanced genetic medicine in development for AATD, which has the potential to fundamentally change the treatment paradigm for patients. In addition, we completed dosing for all adult and adolescent SCD patients in the BEACON trial of risto-cel and received FDA clearance of the IND for BEAM-304 in PKU, paving the way to the clinic for this next potentially high-value franchise. Looking ahead, we believe Beam is positioned to achieve several important milestones, including updated clinical data for BEAM-302 at the ERS Congress, rapid enrollment in the BEAM-302 pivotal cohort, first-in-human data for BEAM-301 in GSDIa, and the expected BLA submission for risto-cel. With the continued expansion and advancement of our base editing pipeline, we have the potential to deliver transformative therapies for many patients with serious genetic diseases.”
Second Quarter 2026 and Recent Progress and Anticipated Milestones
Liver-targeted Genetic Disease Franchise
BEAM-302: Beam’s lead genetic disease program is designed to be a best-in-class and first-in-class liver-targeting therapy for alpha-1 antitrypsin deficiency (AATD) that directly corrects the root cause of the disease and therefore has the potential to address both liver and lung manifestations of AATD.
BEAM-304: BEAM-304 is designed to leverage Beam’s proprietary and clinically validated base editing technology and lipid nanoparticle (LNP) delivery capabilities to directly and durably correct mutations in the phenylalanine hydroxylase (PAH) gene that cause phenylketonuria (PKU). Beam aims to advance BEAM-304 using an innovative platform approach with the goal of creating mutation-specific base editors for the majority of patients with PKU.
BEAM-301: BEAM-301 aims to correct one of the most common disease-causing mutations, R83C, in patients with glycogen storage disease type Ia (GSDIa).
Hematology Franchise
Risto-cel: Ristoglogene autogetemcel (risto-cel, formerly known as BEAM-101) is an investigational autologous cell therapy with a potential best-in-class profile for the treatment of sickle cell disease (SCD).
Next-generation Programs in Sickle Cell Disease and Hematology:
Second Quarter 2026 Financial Results
Cash Runway
Beam expects that its cash, cash equivalents and marketable securities as of June 30, 2026, together with an additional $200 million expected to be drawn from the company’s facility with Sixth Street, will fund anticipated operating expenses and capital expenditure requirements into mid-2029, funding the company through the anticipated launch of risto-cel in SCD, execution of the BEAM-302 pivotal development plan in AATD, and clinical proof of concept for BEAM-304 in PKU.
About Beam Therapeutics
Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform with integrated gene editing, delivery and internal manufacturing capabilities. Beam’s suite of gene editing technologies is anchored by base editing, a proprietary technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This has the potential to enable a wide range of therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing lifelong cures to patients suffering from serious diseases.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Investors are cautioned not to place undue reliance on these forward-looking statements, including, but not limited to, statements related to: the therapeutic applications and potential of our technology, including with respect to SCD, AATD, PKU and GSDIa; our plans, and anticipated timing, to advance our programs and present data from ongoing clinical trials; the clinical trial designs and expectations for risto-cel, BEAM-103, BEAM-301, BEAM-302 and BEAM-304; our planned submission of a BLA for risto-cel; our expectations regarding the anticipated launch of risto-cel; the potential for an accelerated approval path for BEAM-302; our expected presentations at upcoming medical conferences, including at the ERS Congress; our anticipated regulatory interactions and filings; our expectations regarding the funds that will be available to draw under our credit facility; the sufficiency of our capital resources to fund operating expenses and capital expenditure requirements and the period in which such resources are expected to be available; and our ability to develop lifelong, curative, precision genetic medicines for patients through base editing. Each forward-looking statement is subject to important risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statement, including, without limitation, risks and uncertainties related to: our ability to develop, obtain regulatory approval for, and commercialize our product candidates, which may take longer or cost more than planned; our ability to raise additional funding, which may not be available; our ability to obtain, maintain and enforce patent and other intellectual property protection for our product candidates; the uncertainty that our product candidates will receive regulatory approval necessary to initiate or continue human clinical trials; that preclinical testing of our product candidates and preliminary or interim data from preclinical studies and clinical trials may not be predictive of the results or success of ongoing or later clinical trials; that initiation and enrollment of, and anticipated timing to advance, our clinical trials may take longer than expected; that our product candidates, including the delivery modalities we rely on to administer them, may cause serious adverse events; that we may not achieve the funding milestones under our credit facility; that our product candidates may experience manufacturing or supply interruptions or failures; risks related to competitive products; and the other risks and uncertainties identified under the headings “Risk Factors Summary” and “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025, and in any subsequent filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by applicable law.
Contacts:
Investors:
Holly Manning
Beam Therapeutics
hmanning@beamtx.com
Media:
Josie Butler
1AB
josie@1abmedia.com
Condensed Consolidated Balance Sheet Data (unaudited) |
|
|||||||
(in thousands) |
|
|||||||
|
|
|
|
|
|
|
||
|
|
June 30, |
|
|
December 31, |
|
||
Cash, cash equivalents, and marketable securities |
|
$ |
1,152,927 |
|
|
$ |
1,245,210 |
|
Total assets |
|
|
1,386,355 |
|
|
|
1,481,177 |
|
Total liabilities |
|
|
318,913 |
|
|
|
242,819 |
|
Total stockholders’ equity |
|
|
1,067,442 |
|
|
|
1,238,358 |
|
Condensed Consolidated Statement of Operations (unaudited) |
|
|||||||||||||||
(in thousands, except share and per share data) |
|
|||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
|
Three Months Ended June 30, |
|
|
Six Months Ended June 30, |
|
||||||||||
|
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
||||
License and collaboration revenue |
|
$ |
490 |
|
|
$ |
8,466 |
|
|
$ |
32,228 |
|
|
$ |
15,936 |
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Research and development |
|
|
95,096 |
|
|
|
101,758 |
|
|
|
199,620 |
|
|
|
200,574 |
|
General and administrative |
|
|
31,947 |
|
|
|
26,859 |
|
|
|
66,376 |
|
|
|
54,799 |
|
Total operating expenses |
|
|
127,043 |
|
|
|
128,617 |
|
|
|
265,996 |
|
|
|
255,373 |
|
Loss from operations |
|
|
(126,553 |
) |
|
|
(120,151 |
) |
|
|
(233,768 |
) |
|
|
(239,437 |
) |
Other income (expense): |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Change in fair value of derivative liabilities |
|
|
(4,200 |
) |
|
|
1,300 |
|
|
|
(1,700 |
) |
|
|
4,500 |
|
Change in fair value of non-controlling equity investments |
|
|
338 |
|
|
|
4,415 |
|
|
|
354 |
|
|
|
2,334 |
|
Change in fair value of contingent consideration liabilities |
|
|
(205 |
) |
|
|
(28 |
) |
|
|
309 |
|
|
|
(55 |
) |
Gain on sale of equity method investment |
|
|
455 |
|
|
|
— |
|
|
|
455 |
|
|
|
— |
|
Interest and other income (expense), net |
|
|
7,487 |
|
|
|
12,326 |
|
|
|
17,354 |
|
|
|
22,190 |
|
Total other income (expense) |
|
|
3,875 |
|
|
|
18,013 |
|
|
|
16,772 |
|
|
|
28,969 |
|
Net loss |
|
$ |
(122,678 |
) |
|
$ |
(102,138 |
) |
|
$ |
(216,996 |
) |
|
$ |
(210,468 |
) |
Unrealized gain (loss) on marketable securities |
|
|
(1,119 |
) |
|
|
(150 |
) |
|
|
(3,300 |
) |
|
|
(669 |
) |
Comprehensive loss |
|
$ |
(123,797 |
) |
|
$ |
(102,288 |
) |
|
$ |
(220,296 |
) |
|
$ |
(211,137 |
) |
Net loss per common share, basic and diluted |
|
$ |
(1.18 |
) |
|
$ |
(1.00 |
) |
|
$ |
(2.09 |
) |
|
$ |
(2.21 |
) |
Weighted-average common shares outstanding, basic and diluted |
|
|
104,326,669 |
|
|
|
101,995,184 |
|
|
|
103,797,276 |
|
|
|
95,023,977 |
|